Microbot Medical Expands LIBERTY Robotic System into Michigan Health System
Event summary
- Microbot Medical's LIBERTY Endovascular Robotic System adopted by a major Michigan health system, marking its first in the state and Midwest U.S.
- Follows recent adoption in North Carolina, expanding LIBERTY’s presence across strategic U.S. regions.
- LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
- U.S. market for peripheral endovascular procedures encompasses approximately 2.5 million procedures annually.
The big picture
Microbot Medical's expansion into Michigan underscores growing demand for robotic solutions in peripheral endovascular procedures. The adoption by major health systems validates the company's transition to full market release in the U.S., highlighting the shift towards advanced robotic technology in vascular care. The 2.5 million annual procedures in the U.S. market present a significant commercial opportunity.
What we're watching
- Market Penetration
- The pace at which Microbot Medical can secure additional health system customers in new regions.
- Regulatory Approvals
- Whether the recent Israeli regulatory approval will accelerate international expansion.
- Physician Adoption
- How quickly physicians and hospital leaders integrate LIBERTY into routine vascular care workflows.